Entries by CAPTIS

Knopp Biosciences, University of Leicester release details of phase 2 trial of dexpramipexole in severe eosinophilic asthma

The 52-week, randomized, double-blind, placebo-controlled trial will evaluate whether dexpramipexole is associated with a reduction in asthma exacerbations. Fifteen severe asthma centers across the United Kingdom (UK) will The post Knopp Biosciences, University of Leicester release details of phase 2 trial of dexpramipexole in severe eosinophilic asthma appeared first on Pharmaceutical Business review.

Phathom Pharmaceuticals announces initiation of pivotal phase 3 clinical trial for vonoprazan in erosive esophagitis

PHALCON-EE is a randomized, double-blind, two-phase, multicenter Phase 3 trial that is planned to enroll approximately 1,000 patients with EE in the U.S. and Europe. The first phase The post Phathom Pharmaceuticals announces initiation of pivotal phase 3 clinical trial for vonoprazan in erosive esophagitis appeared first on Pharmaceutical Business review.

Astellas Pharma to buy Audentes Therapeutics for $3bn

Under the deal, Astellas US Holding wholly-owned subsidiary Asilomar Acquisition will acquire Audentes by paying $60 per share in cash. Audentes chairman and CEO Matthew Patterson said: “With The post Astellas Pharma to buy Audentes Therapeutics for $3bn appeared first on Pharmaceutical Business review.

Merck’s Keytruda gets FDA priority review for high-risk NMIBC

The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the treatment of patients having Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle The post Merck’s Keytruda gets FDA priority review for high-risk NMIBC appeared first on Pharmaceutical Business review.

LUNAC Therapeutics-led project awarded £3.14m under Innovate UK Biomedical Catalyst Programme, to develop next-generation anticoagulant

The funding will be used to develop an innovative anticoagulant treatment with minimal bleeding risk, to better meet patient need. The 18-month preclinical drug discovery project brings together The post LUNAC Therapeutics-led project awarded £3.14m under Innovate UK Biomedical Catalyst Programme, to develop next-generation anticoagulant appeared first on Pharmaceutical Business review.

Medincell receives $19m grant for mdc-WWM programme

It aims to fund preclinical activities and a phase 1 clinical trial for the injectable six-month bioresorbable contraceptive (mdc-WWM). The grant is structured in advanced installments to cover The post Medincell receives $19m grant for mdc-WWM programme appeared first on Pharmaceutical Business review.